Argenica Therapeutics Limited (ASX:AGN)
Australia · Delayed Price · Currency is AUD 0.2200
+0.0050 (2.33%)
Mar 4, 2026, 3:03 PM AEST
Argenica Therapeutics Revenue
Argenica Therapeutics had revenue of 626.74K AUD in the half year ending December 31, 2025, a decrease of -73.36%. This brings the company's revenue in the last twelve months to 1.01M, down -67.31% year-over-year. In the fiscal year ending June 30, 2025, Argenica Therapeutics had annual revenue of 3.21M with 23.70% growth.
Revenue (ttm)
1.01M
Revenue Growth
-67.31%
P/S Ratio
28.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
28.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.21M | 615.81K | 23.70% |
| Jun 30, 2024 | 2.60M | 848.04K | 48.46% |
| Jun 30, 2023 | 1.75M | 1.49M | 575.38% |
| Jun 30, 2022 | 259.10K | -36.98K | -12.49% |
| Jun 30, 2021 | 296.08K | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Neurotech International | 7.07M |
| Neurizon Therapeutics | 5.98M |
| Amplia Therapeutics | 5.01M |
| Proteomics International Laboratories | 3.21M |
| Noxopharm | 2.68M |
| Entropy Neurodynamics | 1.58M |
| Avecho Biotechnology | 1.24M |